Natera Is Growing Nearly 40% a Year – But the Stock Has Already Priced In the Good News

Natera, Inc. sits just a few dollars below its two-year high, and the market has rewarded the genetic-testing company’s growth story with one of the richest valuations this Natera, Inc. stock analysis has covered: a Price/Book ratio above 25x on a company that still isn’t profitable. Revenue is compounding at roughly 38% a year, but the scoring model’s verdict is more cautious than the chart suggests.

What Is Happening With the Stock Price

Shares trade at $318.35, near the top of their two-year range of $112.90 to $322.10 – a range position of roughly 98%, putting Natera firmly at the upper end of where it has traded over the past two years. Market cap stands at $45.89 billion. That kind of persistent strength typically reflects investor confidence in the underlying growth trajectory rather than near-term earnings, since the company remains unprofitable on a net basis.

Quality: Is This a Financially Sound Business?

Natera’s Quality Score of 52/100 reflects a business with real strengths and real gaps. Gross margin is healthy at 65.2%, showing the core testing business generates solid unit economics. But operating margin is -10.3% and net profit margin is -7.1%, translating to an EPS of -$1.35 and negative returns – Return on Equity of -12.5% and Return on Assets of -8.1%. Notably, EV/EBITDA comes in at -203.08, an unusual figure driven by negative EBITDA rather than a negative enterprise value – a sign the company is still burning cash at the operating level even as gross margins hold up. The balance sheet is the offsetting strength: a current ratio of 3.00, quick ratio of 2.74, and low debt-to-equity of 0.13 give Natera ample room to keep investing without near-term solvency concerns. Free cash flow is modestly positive at $104 million (TTM), a small but real cushion.

Growth: Does This Company Have Real Upside?

This is where the Natera, Inc. stock analysis turns more constructive: a Growth Score of 75/100. Revenue reached $2.7 billion over the trailing twelve months, up 37.7% TTM and compounding at a 41.1% five-year CAGR – durable, high double-digit expansion by any standard. Earnings growth (TTM) is not meaningful since the company remains unprofitable, so the growth case currently rests on the top line and gross-margin trajectory rather than earnings momentum. An EV/Revenue multiple of 16.84 shows the market is already paying a substantial premium for that growth to continue.

Opportunity: Is Now a Good Time to Enter?

The Opportunity Score of just 2/100 is the clearest signal in this analysis. With no P/E ratio available since Natera is still unprofitable, valuation falls back on Price/Book at 25.61x and EV/Revenue at 16.84x – both stretched for a company without positive earnings. FCF yield is thin at 0.2%. Combined with a range position near the top of the two-year band, the entry-point case is weak: the stock is priced for continued strong execution, leaving little room for a growth slowdown.

Natera, Inc. Stock Analysis: The Bottom Line

Natera pairs a genuinely strong growth story – high-30s revenue expansion and a healthy balance sheet – with a valuation that already assumes the good times continue and a profitability profile that hasn’t caught up yet. That combination is why the model lands on a Hold: Growth is a clear positive, Quality is mixed with a solid balance sheet offset by ongoing losses, and Opportunity is weak given the price and lack of earnings support. Investors weighing this name might watch for a path to sustained profitability or a valuation reset before the risk/reward improves; the growth trajectory alone hasn’t been enough to lift the Opportunity score.